Form 4: Cogent Biosciences Chief Commercial Officer Acquires Shares in Open Market Transaction

Cogent Biosciences' Chief Commercial Officer, Cole Pinnow, acquired 43,750 shares of common stock at an average price of $7.598 per share on January 14, 2025.

Summary

• Cole Pinnow, the Chief Commercial Officer of Cogent Biosciences, purchased 43,750 shares of the company's common stock on January 14, 2025.
• The shares were acquired through multiple transactions at prices ranging from $7.53 to $7.60, with a weighted average price of $7.598 per share.
• Following the transaction, Mr. Pinnow directly owns 45,848 shares of Cogent Biosciences common stock.
• This includes 1,398 shares acquired through the company's 2018 Employee Stock Purchase Plan on December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an insider's confidence in the company through a share purchase. However, it's a routine transaction and not a major event.

Positives

• The purchase of shares by a key executive like the Chief Commercial Officer can be seen as a positive sign of confidence in the company's future prospects.
• The transaction increases the executive's stake in the company, aligning his interests with those of other shareholders.

Industry Context

This is a routine SEC Form 4 filing, which is common for publicly traded companies when insiders buy or sell shares. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for all publicly traded companies in the US, and this filing is consistent with those standards.
• The transaction is similar to other insider purchases in the biotech industry, where executives often acquire shares to align their interests with shareholders.

Stakeholder Impact

• The share purchase by a key executive may positively influence investor confidence.
• The transaction has a minor positive impact on shareholders as it aligns management's interests with theirs.

Key Dates

Keywords

Cogent Biosciences, COGT, insider trading, stock purchase, executive, Chief Commercial Officer, Cole Pinnow, Form 4, SEC filing